India is rapidly emerging as a global powerhouse in the Active Pharmaceutical Ingredient (API) sector. With over 2000 APIs in production and a projected growth rate of 13.7% CAGR, India has solidified its position as the world’s third-largest API producer. Notably, it contributes 57% of the WHO’s prequalified API list, reflecting its critical role in global healthcare.

Indian pharma companies lead with cost-effective API production, enabling access to affordable, high-quality medicines worldwide. Backed by a robust manufacturing base, India exports APIs to over 200 countries, establishing itself as a key player in the global pharmaceutical supply chain.

Compliance with international standards, such as USFDA, WHO-GMP, and CEP ensures reliability, safety, and quality. Moreover, Indian manufacturers offer tailored formulations to meet diverse regulatory and market demands, ensuring flexibility and a competitive edge.

Innovation remains at the core, with continuous R&D driving better drug efficacy and patient outcomes. Indian APIs also span a wide therapeutic spectrum, from cardiovascular care to oncology.

At Coral Drugs, we are proud to contribute to this momentum. Specializing in high-quality APIs, we are committed to excellence, sustainability, and global collaboration.

Partner with Coral Drugs to shape the future of healthcare together.

Follow us on LinkedIn for more insights into the API industry, pharma innovation, and global healthcare trends.

‍